License and Collaboration Agreements - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified |
1 Months Ended | 2 Months Ended | 3 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended | 1 Months Ended | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2013
|
Mar. 31, 2013
Naloxegol [Member]
|
Mar. 31, 2013
AstraZeneca AB [Member]
|
Mar. 31, 2013
AstraZeneca AB [Member]
Naloxegol [Member]
|
Mar. 31, 2013
AstraZeneca AB [Member]
Naloxegol fixed-dose combination programs [Member]
|
Mar. 31, 2013
Roche [Member]
PEGASYS [Member]
|
Mar. 31, 2013
Roche [Member]
MIRCERA [Member]
|
Feb. 29, 2012
Roche [Member]
MIRCERA [Member]
Performance-based milestone payments [Member]
|
Feb. 29, 2012
Roche [Member]
MIRCERA [Member]
Upfront payment arrangement [Member]
|
Mar. 31, 2013
Roche [Member]
MIRCERA [Member]
Upfront payment arrangement [Member]
Performance-based milestone payments [Member]
|
Mar. 31, 2013
Amgen, Inc. [Member]
|
Mar. 31, 2013
Baxter Healthcare [Member]
Hemophilia [Member]
|
Mar. 31, 2013
Affymax, Inc. [Member]
Omontys [Member]
|
Mar. 31, 2013
Other [Member]
|
Apr. 30, 2013
Bayer Healthcare LLC [Member]
|
Mar. 31, 2013
Bayer Healthcare LLC [Member]
|
Dec. 31, 2012
Bayer Healthcare LLC [Member]
|
Dec. 31, 2007
Bayer Healthcare LLC [Member]
Performance-based milestone payments [Member]
|
Dec. 31, 2007
Bayer Healthcare LLC [Member]
Upfront payment arrangement [Member]
|
|
Deferred Revenue Arrangement [Line Items] | |||||||||||||||||||
Potential future additional payments for development milestones | $ 161.1 | $ 28.0 | $ 73.1 | $ 50.0 | |||||||||||||||
Contingent payments receivable based on development events regulatory to be pursued and completed solely by others | 140.0 | 95.0 | 235.0 | 75.0 | |||||||||||||||
Deferred revenue | 14.1 | 20.1 | 37.9 | 7.0 | 23.8 | ||||||||||||||
Received upfront and milestone payments | 22.0 | 5.0 | 27.0 | 20.0 | 40.0 | ||||||||||||||
Performance milestone payments recorded as a liability to Bayer | 10.0 | 10.0 | |||||||||||||||||
Development milestones achieved | $ 10.0 |